These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30421622)

  • 1. Incurred sample reproducibility: what have we learned and how can we build on our learnings?
    Timmerman P
    Bioanalysis; 2018 Nov; 10(21):1707-1709. PubMed ID: 30421622
    [No Abstract]   [Full Text] [Related]  

  • 2. A look back at the incurred sample reanalysis.
    Vazvaei F
    Bioanalysis; 2018 Nov; 10(21):1711-1713. PubMed ID: 30412679
    [No Abstract]   [Full Text] [Related]  

  • 3. Incurred sample reproducibility.
    Vazvaei F; Timmerman P
    Bioanalysis; 2018 Nov; 10(21):1705-1706. PubMed ID: 30810353
    [No Abstract]   [Full Text] [Related]  

  • 4. Incurred sample reproducibility: 10 years of experiences: views and recommendations from the European Bioanalysis Forum.
    Kall MA; Michi M; van der Strate B; Freisleben A; Stoellner D; Timmerman P
    Bioanalysis; 2018 Nov; 10(21):1723-1732. PubMed ID: 30412676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incurred sample reanalysis: 'too much of a good thing?'.
    Fluhler EN
    Bioanalysis; 2018 Nov; 10(21):1719-1721. PubMed ID: 30301361
    [No Abstract]   [Full Text] [Related]  

  • 6. Incurred sample reproducibility in pharmacokinetic bioanalysis: pros and cons from a CRO perspective.
    Timmons BM; Hay L; Gorman J; Stouffer B
    Bioanalysis; 2018 Nov; 10(21):1715-1717. PubMed ID: 30412674
    [No Abstract]   [Full Text] [Related]  

  • 7. Incurred sample reanalysis in AstraZeneca small molecule portfolio - what have we learned and where do we go next?
    Arfvidsson C; Wilson A; Heijer M; Bailey C; Severin P; Milligan F; Ngeny M; Dayton B; Li Y; Cape S
    Bioanalysis; 2018 Nov; 10(21):1733-1745. PubMed ID: 30325197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decade of incurred sample reanalysis: failures, investigations and impact.
    Lee LB; Wickremsinhe ER
    Bioanalysis; 2018 Nov; 10(21):1767-1772. PubMed ID: 30301360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory methods for allergen extract analysis and quality control.
    Grier TJ
    Clin Rev Allergy Immunol; 2001 Oct; 21(2-3):111-40. PubMed ID: 11725601
    [No Abstract]   [Full Text] [Related]  

  • 10. Bioanalytical method validation: notable points in the 2009 draft EMA Guideline and differences with the 2001 FDA Guidance.
    Smith G
    Bioanalysis; 2010 May; 2(5):929-35. PubMed ID: 21083222
    [No Abstract]   [Full Text] [Related]  

  • 11. ISR: what have we learned after a decade of experience?
    Verhaeghe T
    Bioanalysis; 2018 Nov; 10(21):1747-1753. PubMed ID: 30301364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incurred sample reanalysis at GSK: what have we learned?
    Summerfield SG; Barfield M; White SA
    Bioanalysis; 2018 Nov; 10(21):1755-1766. PubMed ID: 30325209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Industry Perspective on Standardizing Food-Effect Studies for New Drug Development.
    Marroum PJ; Nuthalapati S; Parikh A; Shebley M; Hoffman D; Zha J; Khatri A; Awni WM
    Clin Pharmacokinet; 2018 Aug; 57(8):901-909. PubMed ID: 29460023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Medicines Agency guideline on bioanalytical method validation: what more is there to say?
    Smith G
    Bioanalysis; 2012 May; 4(8):865-8. PubMed ID: 22533559
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis.
    Lowes S; Jersey J; Shoup R; Garofolo F; Savoie N; Mortz E; Needham S; Caturla MC; Steffen R; Sheldon C; Hayes R; Samuels T; Di Donato L; Kamerud J; Michael S; Lin ZJ; Hillier J; Moussallie M; de Souza Teixeira L; Rocci M; Buonarati M; Truog J; Hussain S; Lundberg R; Breau A; Zhang T; Jonker J; Berger N; Gagnon-Carignan S; Nehls C; Nicholson R; Hilhorst M; Karnik S; de Boer T; Houghton R; Smith K; Cojocaru L; Allen M; Harter T; Fatmi S; Sayyarpour F; Vija J; Malone M; Heller D
    Bioanalysis; 2011 Jun; 3(12):1323-32. PubMed ID: 21679026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Justifying the lack of incurred sample reproducibility in a study: considerations and strategies.
    Gagnon-Carignan S; Lachance S; Saint-Laurent A; Gendron M; Lévesque A
    Bioanalysis; 2015; 7(2):221-7. PubMed ID: 25587838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incurred sample reanalysis: a global transformation.
    Viswanathan CT
    Bioanalysis; 2011 Dec; 3(23):2601-2. PubMed ID: 22136048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discussion: The FDA is Unprepared for Personalized Medicine.
    Tabarrok A
    Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulatory observations in bioanalytical determinations.
    Viswanathan CT
    Bioanalysis; 2010 Jul; 2(7):1325-9. PubMed ID: 21083243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA/critical path initiative/Duke-Margolis center for health policy public workshop on analytical validation of assays for biomarker qualification: an update on the White Paper.
    Piccoli SP
    Bioanalysis; 2018 Jun; 10(12):893-896. PubMed ID: 29924636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.